QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new sta

Bank of America Corp DE grew its stake in shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA) by 25

Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Pha

Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and

Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application s

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application sub

Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Bel

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submit

Arete Wealth Advisors LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ: PVLA) dur

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company

Fifth Third Bancorp bought a new stake in Palvella Therapeutics, Inc. (NASDAQ: PVLA) in the undefine

US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid

Brings more than 25 years of experience advancing and commercializing high-impact therapies for seri

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average pri

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They'

Palvella remains on track to submit an NDA in the second half of 2026Microcystic lymphatic malformat

Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malforma

Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biop

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a

In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as "Much Improve

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on t

The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company's co

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:P

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformat

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the

Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage bio

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lea

Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform

BTIG analyst Jeet Mukherjee maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises

Palvella Therapeutics, Inc. ("Palvella") (Nasdaq: PVLA), a clinical-stage biopharmaceutical

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with

Palvella Therapeutics shares are trading higher after reporting topline data from its Phase 3 SELVA